NCT01200472 - Efficacy Study of Apremilast (CC-10004) in Subjects With Erosive Hand Osteoarthritis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

August 31, 2013

Study Completion Date

October 31, 2013

Conditions

Erosive Osteoarthritis of the Hand

Interventions

DRUG

Apremilast

Apremilast is supplied as 10 mg capsules for oral administration. After a 7-day titration phase patients will receive 20 mg PO BID apremilast.

DRUG

Placebo

Placebo capsules identical to apremilast

Trial Locations (3)

Prof. Matthias Schneider, Universitätsklinikum Düsseldorf, Klinik für Endokrinologie, Diabetologie und Rheumatologie, Düsseldorf

Prof. Ulf Müller-Ladner, Kerckhoff-Klinik, Bad Nauheim

Prof. G. Schett, University Hospital Erlangen, Erlangen